This $460,625 Project Grant awarded by the National Institute on Aging under CFDA Program 93.866 (Aging Research) aims to gain a mechanistic understanding of the role of cellular senescence in the pathogenesis of Alzheimer's disease. The grant supports research using human induced pluripotent stem cell-based Alzheimer's disease models to dissect the functional consequences of activating the p53/p21 and p16 senescence pathways in differentiated cortical neurons and cerebral organoids. The goal is...
This $522,500 Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) supports research by The Salk Institute for Biological Studies in La Jolla, California to investigate the role of astrocytes, a type of brain cell, in age-related motor decline. The research aims to determine if reducing the expression of the STAT1 transcription factor in aged astrocytes can revert aging signatures, rescue synaptic deficits, and improve motor function in the...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $794,341 to the University of Illinois to investigate the roles of cellular senescence and blood-brain barrier dysfunction in Alzheimer's disease development and progression. The key objectives are to understand how viral and bacterial infections can initiate blood-brain barrier impairment and increase inflammation, leading to accelerated Alzheimer's disease pathology. The research...
This federal Project Grant award, funded by the National Institute on Aging (part of the Department of Health and Human Services) under the Aging Research program (CFDA 93.866), is focused on evaluating a novel therapeutic approach to target neuroinflammation for protecting against brain aging and Alzheimer's disease-related pathology. The $281,962 award, with an end date of June 30, 2026, will support a series of preclinical studies in aging wild-type mice and transgenic mouse models of amyloid...
The U.S. Department of Health and Human Services' National Institute on Aging awarded a $223,622 Project Grant (CFDA 93.866 - Aging Research) to The University of Texas Health Science Center at San Antonio to investigate the pathogenic effects of senescent cells on their microenvironments and their role in human brain aging and Alzheimer's disease and related dementias (ADRD). The project aims to generate spatial omics data from ADRD brains and corresponding mouse models, and leverage deep...
This Project Grant award from the National Institute on Aging's Aging Research federal grant program (CFDA 93.866) provides $871,419 to the University of Washington to conduct research on the role of microglia, the brain's immune cells, in the pathogenesis of Alzheimer's disease. The research aims to characterize molecular profiles and spatial organization of microglia across the adult age spectrum, both with and without Alzheimer's disease, through single-nucleus RNA sequencing of over 5,000...
This Project Grant award from the National Institute on Aging (NIA) under CFDA 93.866 - Aging Research provides $2,288,327 to the University of California, San Diego (UCSD) to investigate early determinants of Alzheimer's disease (AD) using age-equivalent neurons derived from mild cognitive impairment (MCI) patients. The research aims to better understand the intersection of polygenic risk factors, biological aging, and key molecular pathways that initiate and drive MCI, with the goal of...
The National Institute on Aging (NIA), under the Aging Research Federal Grant Program (CFDA 93.866), awarded a 5-year Project Grant totaling $508,525 to the Mayo Clinic in Rochester, Minnesota. The grant supports research to investigate the role of adipose (fat) senescent cells in cognitive function and the progression of Alzheimer's disease. Key components of the project include: Determining the potential effects of aging- or obesity-driven accumulation of senescent cells in adipose tissue on...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $842,175 to the J. David Gladstone Institutes, a non-profit biomedical research organization in San Francisco, to explore the role of the NOX2 enzyme in mediating Alzheimer's disease pathologies. The goal is to assess the therapeutic potential of a novel NOX2 inhibitor (GSK2795039) in mitigating amyloid-beta and tau-induced brain dysfunction, network hyperactivity, and cognitive deficits...
This Project Grant award, totaling $10,847,672, was provided by the National Institute on Aging (NIA) under the Aging Research federal grant program (CFDA 93.866) to the J. David Gladstone Institutes, a non-profit biomedical research organization in San Francisco. The grant will fund a multidisciplinary research effort to elucidate the molecular and cellular mechanisms underlying cerebral amyloid angiopathy (CAA) and its relationship to Alzheimer's disease pathology. Key aspects include...